Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Renal osteodystrophy and hypercalcemia

M Cohen-Solal1, J L Sebert

  • 1Service de Rhumatologie, Centre Hospitalier Universitaire, Amiens, France.

Current Opinion in Rheumatology
|May 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of sphingosine 1-phosphate protects mice against chondrocyte catabolism and osteoarthritis.

Osteoarthritis and cartilage·2021
Same author

The Matrilin-3 T298M mutation predisposes for post-traumatic osteoarthritis in a knock-in mouse model.

Osteoarthritis and cartilage·2020
Same author

Identification of TGFβ signatures in six murine models mimicking different osteoarthritis clinical phenotypes.

Osteoarthritis and cartilage·2020
Same author

Microcracks in subchondral bone plate is linked to less cartilage damage.

Bone·2019
Same author

Secular trends of hip fractures in France: impact of changing characteristics of the background population.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2018
Same author

Etelcalcetide: injectable calcimimetic for the treatment of secondary hyperparathyroidism in hemodialysis-dependent patients.

Drugs of today (Barcelona, Spain : 1998)·2017
Same journal

New approaches to the management of cutaneous lupus.

Current opinion in rheumatology·2026
Same journal

"Updates in chronic nonbacterial osteomyelitis: emerging insights across the age spectrum".

Current opinion in rheumatology·2026
Same journal

Difficult-to-treat, complex-to-manage, treatment-refractory spondyloarthritis: semantics or substance?

Current opinion in rheumatology·2026
Same journal

Update on IgA nephropathy: implications for treatment in IgA vasculitis: a guide for rheumatologists.

Current opinion in rheumatology·2026
Same journal

Polyarticular juvenile idiopathic arthritis: insights from genetic studies on disease risk and pathogenesis.

Current opinion in rheumatology·2026
Same journal

Immune dysregulation in children with Down syndrome: clinical implications and emerging therapies.

Current opinion in rheumatology·2026
See all related articles

Aluminum-related bone disease in uremic patients can be prevented by avoiding aluminum-phosphate binders. Other factors, including dialysis membranes and immunosuppressants, also impact bone health.

Area of Science:

  • Nephrology
  • Endocrinology
  • Bone Metabolism

Background:

  • Aluminum-related bone disease is a significant complication in uremic patients.
  • Adynamic bone disease can arise from factors beyond aluminum exposure.
  • Primary hyperparathyroidism is a common cause of hypercalcemia.

Purpose of the Study:

  • To review the prevention and management of bone disease in uremic patients.
  • To discuss the role of primary hyperparathyroidism and its treatment.
  • To highlight advancements in diagnosing and managing hypercalcemia.

Main Methods:

  • Literature review of aluminum bone disease, adynamic bone disease, and primary hyperparathyroidism.
  • Discussion of diagnostic tools for parathyroid hormone (PTH) and PTH-related protein (PTHrP).

Related Experiment Videos

  • Evaluation of bisphosphonates for hypercalcemia management.

    • Main Results:

    • Oral calcium carbonate can replace aluminum-phosphate binders to prevent aluminum bone disease.
    • Dialysis membranes and immunosuppressants may influence bone disease post-transplantation.
    • New immunoassays for intact PTH and PTHrP demonstrate diagnostic value.
    • Bisphosphonates are effective for hypercalcemia in malignancy.

    Conclusions:

    • Aluminum bone disease is preventable in uremia.
    • Multiple factors contribute to bone disease in renal failure.
    • Primary hyperparathyroidism management requires careful consideration.
    • Novel diagnostic and therapeutic options improve hypercalcemia management.